We included nine randomised controlled trials which compared the efficacy and safety of 8 to 24 weeks of chromium supplementation and placebo in overweight or obese adults (i.e. Chromium picolinate is one of several chemical compounds of chromium sold as a nutritional supplement as a potential aid to weight loss. Chromium is also said to suppress the appetite and stimulate the production of heat by the body, thus increasing energy expenditure. It is generally believed that chromium may help to reduce a person's weight by decreasing the amount of fat in the body. Chromium increases the activity of insulin, and dietary supplementation with chromium has produced improvements in glucose metabolism which may lower blood glucose being important for overweight people with diabetes. the chemical reactions involved in breaking down these molecules to a form suitable for absorption by the body).
No study reported on all‐cause mortality, morbidity, health‐related quality of life or socioeconomic effects.Ĭhromium picolinate supplementation for overweight or obese peopleĪre chromium supplements useful for reducing body weight in overweight or obese adults?Ĭhromium is an essential nutrient (trace element) required for the normal metabolism of carbohydrate, protein and fat (i.e. Two participants receiving placebo discontinued due to adverse events one event was reported as serious. There were two serious adverse events and study dropouts in participants taking 1000 µg CrP, and one serious adverse event in an individual taking 400 µg CrP. Only three studies provided information on adverse events (low‐quality evidence (GRADE)). No firm evidence and no dose gradient could be established when comparing different doses of CrP with placebo for various weight loss measures (body weight, body mass index, percentage body fat composition, change in waist circumference). However, in order to find out if CrP works in general, we also analysed the effect of all pooled CrP doses versus placebo on body weight only.Īcross all CrP doses investigated (200 µg, 400 µg, 500 µg, 1000 µg) we noted an effect on body weight in favour of CrP of debatable clinical relevance after 12 to 16 weeks of treatment: mean difference (MD) ‐1.1 kg (95% CI ‐1.7 to ‐0.4) P = 0.001 392 participants 6 trials low‐quality evidence (GRADE)). We focused this review on investigating which dose of CrP would prove most effective versus placebo and therefore assessed the results according to CrP dose.
#Chromium polynicotinate and weight loss plus#
Three RCTs compared CrP plus resistance or weight training with placebo plus resistance or weight training, the other RCTs compared CrP alone versus placebo.
The RCTs were conducted in the community setting, with interventions mainly delivered by health professionals, and had a short‐ to medium‐term follow up (up to 24 weeks). We evaluated nine RCTs involving a total of 622 participants.
0 kommentar(er)
